2018 ESMO Immuno-Oncology Award Goes to Cornelis Melief

San Francisco, CA USA (UroToday.com) -- The European Society for Medical Oncology (ESMO) has selected Prof. Cornelis Melief to receive the 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer. The distinction will be officially presented to him at the opening keynote and award lecture of this year’s ESMO Immuno-Oncology Congress in Geneva, Switzerland (13-16 December).1

ESMO 2018: The Best of Munich 2018 Congress Genitourinary Tumors, Prostate

Munich, Germany (UroToday.com) Silke Gillessen, MD summarized the highlights of prostate cancer studies presented this year in ESMO.  A total of four important prostate cancer studies in three different prostate cancer settings were presented in this session, deemed to be very important by Dr. Gillessen.

ESMO 2018: Can Biology Help Guide Treatment Decisions in Renal Cancer?

Munich, Germany (UroToday.com) When assessing the completed combination trials in metastatic renal cell carcinoma (mRCC), most studies have met their anticipated endpoints. When all various treatments have been shown to be successful, this makes deciding which treatment will be right for which patients difficult.

ESMO 2018: The Best of Munich 2018 Congress - Genitourinary Tumors, Non-Prostate

Munich, Germany (UroToday.com) Dr. Bono discussed some of the highlights in renal and bladder cancer that were presented this year in ESMO 2018, in Munich.  He first discussed some of the interesting studies in renal cancer. In the last ten years, there have been ten new agents that have been made available for the treatment of metastatic renal cell carcinoma (mRCC). The median survival of these new agents is approximately 28-30 months.

ESMO 2018: Challenging Established Frontline Therapies in Renal Cancer

Munich, Germany (UroToday.com) Dr. Laurence Albiges gave a talk on the challenges faced by established frontline therapies in renal cancer. In the ESMO meeting in 2017, the Checkmate 214 trial was presented, which compared sunitinib to Nivolumab + ipilimumab in the treatment of metastatic renal cell carcinoma (mRCC) patients. This trial demonstrated a benefit in favor of the nivolumab + ipilimumab combination in poor and intermediate risk mRCC patients, with median overall survival (OS) that was not reached compared to 26 months in the sunitinib group, p<0.0001. The complete response rate (CR) was 9% vs. 1% in favor of the combination treatment.

ESMO 2018: WHO-ESMO Workforce Survey: How Can your Country Assure Enough Oncologists for the Future?

Munich, Germany (UroToday.com) When analyzing what kind of health workforce is required in any specific environment. It is important to answer some raised relevant questions:

  1. How many providers are needed?
  2. What type of providers are needed?
  3. How to organize and distribute providers?
  4. How to ensure providers are adequately trained to provide high-quality care.

ESMO 2018: Where Does the World Stand on Global Cancer Control?

Munich, Germany (UroToday.com) Cancer causes 9.6 million deaths per year worldwide (1 in 6 global deaths). This is a higher number than that caused by AIDS, Malaria, and Tuberculosis, combined! Unfortunately, being diagnosed with cancer in a low-income country results in chances of survival of less than 30%. The cancer burden is expected to rise significantly from 18.1 million cases per year in 2018 to 29.9 million cases per year in 2040.

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.